Cannabidiol for Alcohol Use Disorder
Trial Summary
What is the purpose of this trial?
This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.
Will I have to stop taking my current medications?
You may need to stop taking certain medications if they interact with Epidiolex, are antiepileptic, or affect alcohol intake, like disulfiram, naltrexone, acamprosate, or topiramate.
What evidence supports the effectiveness of the drug Cannabidiol (CBD) for treating alcohol use disorder?
Research in mice shows that CBD can reduce alcohol consumption, motivation to drink, and relapse, suggesting it might help with alcohol use disorder. Additionally, a systematic review indicates that CBD has potential benefits in reducing alcohol-related harms and addiction behaviors in preclinical models, although more human studies are needed to confirm these effects.12345
Is cannabidiol (CBD) safe for humans?
How is the drug Cannabidiol (CBD) unique in treating alcohol use disorder?
Cannabidiol (CBD) is unique because it is a nonpsychoactive component of cannabis that has shown promise in reducing alcohol consumption and related harms in preclinical models, without the risk of abuse. Unlike traditional treatments, CBD may offer neuroprotective benefits and reduce alcohol-induced liver damage, but more human studies are needed to confirm these effects.34578
Research Team
Kent Hutchison, PhD
Principal Investigator
University of Colorado, Denver
Eligibility Criteria
This trial is for adults over 21 with moderate to severe Alcohol Use Disorder who drink heavily and want to cut down or stop. They must be able to visit the study site, not use cannabis daily, have no serious psychiatric disorders or recent medical issues, and not take certain medications that affect alcohol intake.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either full spectrum CBD, broad spectrum CBD, or placebo for 12 weeks to assess efficacy in reducing alcohol consumption and related symptoms
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cannabidiol
- Placebo
Cannabidiol is already approved in United States, European Union, Canada for the following indications:
- Seizures associated with Lennox-Gastaut syndrome
- Seizures associated with Dravet syndrome
- Seizures associated with tuberous sclerosis complex
- Seizures associated with Lennox-Gastaut syndrome
- Seizures associated with Dravet syndrome
- Seizures associated with tuberous sclerosis complex
- Seizures associated with Lennox-Gastaut syndrome
- Seizures associated with Dravet syndrome
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator